Carfilzomib 56 mg/m<sup>2</sup> twice-weekly in combination with dexamethasone and daratumumab (KdD) versus daratumumab in combination with bortezomib and dexamethasone (DVd): a matching-adjusted indirect treatment comparison

Weisel, Katja; Nooka, Ajay K.; Terpos, Evangelos; Spencer, Andrew; Goldschmidt, Hartmut; Dirnberger, Franziska; Yusuf, Akeem; Kumar, Shaji

doi:10.1080/10428194.2022.2047962

Cited by 3 publications

(1 citation statement)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the treatment landscape of newly diagnosed and relapsed refractory multiple myeloma, there are a notable lack of robust real-world data comparing the effectiveness of different regimens. While some comparative data exist between DKd and DVd [9], a significant gap remains when it comes to comparing DPd, which incorporates a third-generation immunomodulatory agent (IMiD) with DVd. This void in data is particularly significant considering the distinctive toxicity profile and the intravenous (IV) administration route associated with carfilzomib in the DKd regimen.…”

Section: Introductionmentioning

confidence: 99%

Efficacy and Safety of Daratumumab, Pomalidomide, and Dexamethasone (DPd) Compared to Daratumumab, Bortezomib, and Dexamethasone (DVd) in Daratumumab–Naïve Relapsed Multiple Myeloma

Afrough,

Atrash,

Paul

et al. 2023

Cancers

View full text Add to dashboard Cite

Daratumumab-based combinations with pomalidomide/dexamethasone (DPd), or bortezomib/dexamethasone (DVd), have shown activity in relapsed/refractory multiple myeloma (RRMM) patients. However, no direct comparisons of safety or efficacy of the two regimens have been published to date. We conducted a retrospective study to compare the safety and efficacy of DPd and DVd in daratumumab-naïve RRMM patients. We included 140 daratumumab-naïve patients who had received DPd or DVd for RRMM. Overall, the DPd group had a greater number of patients who had high-risk disease characteristics. Although response was deeper in the DPd group, the median progression-free survival (PFS) and overall survival (OS) were similar between the two groups. The DPd group exhibited a higher incidence of hematologic toxicities, whereas the DVd group had a higher incidence of peripheral neuropathy. The study results showed that while DPd may provide a deeper response, there was no significant difference in PFS or OS compared to DVd. For the high proportion of difficult-to-treat patients, duration of treatment may have contributed to these results, indicating that patient and disease characteristics should be considered when selecting salvage treatments.

show abstract

Section: Introductionmentioning

confidence: 99%

Efficacy and Safety of Daratumumab, Pomalidomide, and Dexamethasone (DPd) Compared to Daratumumab, Bortezomib, and Dexamethasone (DVd) in Daratumumab–Naïve Relapsed Multiple Myeloma

Afrough,

Atrash,

Paul

et al. 2023

Cancers

View full text Add to dashboard Cite

show abstract

Proteasome inhibition in combination with immunotherapies: State-of-the-Art in multiple myeloma

et al. 2023

View full text Add to dashboard Cite

Carfilzomib, daratumumab, and dexamethasone (KdD) vs. lenalidomide-sparing pomalidomide-containing triplet regimens for relapsed/refractory multiple myeloma: an indirect treatment comparison

Weisel,

Dimopoulos,

Beksac

et al. 2024

Leukemia & Lymphoma

View full text Add to dashboard Cite

Carfilzomib 56 mg/m² twice-weekly in combination with dexamethasone and daratumumab (KdD) versus daratumumab in combination with bortezomib and dexamethasone (DVd): a matching-adjusted indirect treatment comparison

Cited by 3 publications

References 36 publications

Efficacy and Safety of Daratumumab, Pomalidomide, and Dexamethasone (DPd) Compared to Daratumumab, Bortezomib, and Dexamethasone (DVd) in Daratumumab–Naïve Relapsed Multiple Myeloma

Efficacy and Safety of Daratumumab, Pomalidomide, and Dexamethasone (DPd) Compared to Daratumumab, Bortezomib, and Dexamethasone (DVd) in Daratumumab–Naïve Relapsed Multiple Myeloma

Proteasome inhibition in combination with immunotherapies: State-of-the-Art in multiple myeloma

Carfilzomib, daratumumab, and dexamethasone (KdD) vs. lenalidomide-sparing pomalidomide-containing triplet regimens for relapsed/refractory multiple myeloma: an indirect treatment comparison

Contact Info

Product

Resources

About

Carfilzomib 56 mg/m2 twice-weekly in combination with dexamethasone and daratumumab (KdD) versus daratumumab in combination with bortezomib and dexamethasone (DVd): a matching-adjusted indirect treatment comparison

Cited by 3 publications

References 36 publications

Efficacy and Safety of Daratumumab, Pomalidomide, and Dexamethasone (DPd) Compared to Daratumumab, Bortezomib, and Dexamethasone (DVd) in Daratumumab–Naïve Relapsed Multiple Myeloma

Efficacy and Safety of Daratumumab, Pomalidomide, and Dexamethasone (DPd) Compared to Daratumumab, Bortezomib, and Dexamethasone (DVd) in Daratumumab–Naïve Relapsed Multiple Myeloma

Proteasome inhibition in combination with immunotherapies: State-of-the-Art in multiple myeloma

Carfilzomib, daratumumab, and dexamethasone (KdD) vs. lenalidomide-sparing pomalidomide-containing triplet regimens for relapsed/refractory multiple myeloma: an indirect treatment comparison

Contact Info

Product

Resources

About

Carfilzomib 56 mg/m² twice-weekly in combination with dexamethasone and daratumumab (KdD) versus daratumumab in combination with bortezomib and dexamethasone (DVd): a matching-adjusted indirect treatment comparison